The Biosimilar Was Too Cheap to Sell. So the Price Went Up Fourfold.
Byooviz relaunched in the US at an average sales price of $1,190, roughly four times its previous level and above the originator it references.
Market Access
Washington Removed the Cushion Under Part D, and Handed the Auditors an Algorithm
Washington ended the subsidy holding Part D premiums down, charged a record number of Medicaid fraud defendants, and put prosecutors’ analytics inside CMS.
NICE Said Yes to the Lung Machine, and Then Attached Four Years of Conditions
NICE conditionally recommended the XVIVO perfusion system for NHS use, with four years of evidence generation and a hub model to end the postcode divide.
Approval Is Day One. In Canada, Patients Wait Another Five Hundred Days.
A Canadian government task force counted the wait for public drug coverage: 200 days for HTA, 195 for price negotiation, then up to 219 more per province.
Italy Ran an Innovation Test for Eight Years.
Italy graded new medicines full, conditional or not innovative for eight years. The 2025 reform abolished the middle grade, because almost nothing ever graduated.
A New Antibiotic Reached a Middle-Income Country Six Months After the US
Thailand approved a first-in-class oral antibiotic for gonorrhoea six months after the US, a benchmark for how fast new medicines can reach lower-income markets.
Argentina Just Made One Agency the Buyer for Five National Hospitals
Argentina published the decree completing its National Agency of Health Establishments, centralising the administration and procurement of five national hospitals.
Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.
Britain believed it had secured an exemption from the MFN reference basket. Washington reads the arrangement differently, and implementation is still being negotiated.
China Stopped Excluding Patented Drugs From Its Price Cuts. Now the Bidder Signs for the Risk.
Eight patent-sensitive molecules were admitted to China’s price-cutting round on one condition: the bidder signs an intellectual property undertaking and carries the risk.
Accord’s Denosumab Biosimilars Launch With Cigna Preferred Status Already Secured
Accord made two interchangeable denosumab biosimilars commercially available with Cigna preferred status already secured on the pharmacy benefit since 1 July.